Skip to main content
Premium Trial:

Request an Annual Quote

Charlotte Clark, David Allison.


Biocept of Carlsbad, Calif., has appointed Charlotte Clark as its chief business officer and executive vice president. Clark comes to the company, which develops three-dimensional hydrogels for protein, nucleic acid, and cell microarrays, from Myelos, where she served as vice president of business development. Clark has also participated in founding four health care companies, including Nereus Pharmaceuticals and Cygnus.

“Charlotte has a tremendous wealth of knowledge working with start-up biotechnology companies in the business development arena and I have no doubt she will be a great asset to the company,” said Soonkap Hahn, Biocept’s chief operating officer and chief technical officer.

David Allison of the University of Alabama at Birmingham’s department of biostatistics has received a five-year, $409,000 grant from the National Science Foundation to establish a national network of microarray researchers. The network will look at issues in interpretation and use of microarray data. “Our aim is to further explore this technology and in turn, improve its effectiveness,” said Allison. (See article on p.5.)

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.